Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Pfizer has made equity investments totaling $46 million in four early-stage drug discovery companies in a program through which the firms will have access to Pfizer’s R&D resources. Pfizer is investing in BioAtla, which is developing monoclonal antibodies called conditionally active biologics as oncology therapies; NextCure, a firm that Pfizer helped form and is focused on immuno-oncology; Cortexyme, specializing in treatments that alter the course of neurodegenerative diseases; and 4D Molecular Therapeutics, a new biopharmaceutical company with its eye on gene therapy.
This article has been sent to the following recipient: